Skip to main content

Advertisement

Log in

Role of the p.E66Q variant of GLA in the progression of chronic kidney disease

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

The p.E66Q variant of the α-galactosidase A gene (GLA) is frequently found during screening for Fabry disease in dialysis patients in Japan. However, recent reports suggest that the p.E66Q variant is not a disease-causing mutation but is a risk factor for cerebral small-vessel occlusion. To evaluate the role of the p.E66Q in the progression of renal diseases, we performed a genetic association study in patients with chronic kidney disease (CKD).

Methods

In this study, we enrolled 1651 chronic hemodialysis and 941 non-dialysis patients who attended medical institutions in the Niigata Prefecture, Japan. The frequency of the p.E66Q allele was compared between hemodialysis and non-dialysis patients, with data from a previously published study of Japanese male newborns. In addition, we compared estimated glomerular filtration rates (eGFR) in the presence or absence of the p.E66Q variant in non-dialysis patients.

Results

Of the 2233 alleles in hemodialysis and 1447 alleles in non-dialysis patients, 21 and nine harbored p.E66Q, respectively. However, p.E66Q allele frequencies did not differ between the two patient groups (0.90 versus 0.62 %, P = 0.35), and no significant difference in p.E66Q allele frequency was observed between male hemodialysis patients and the general Japanese population (0.52 versus 0.63 %, P = 0.67). Moreover, eGFR did not significantly differ between non-dialysis patients with the p.E66Q variant and patients with the wild-type allele (65.5 ± 10.7 versus 62.7 ± 16.6 mL/min/1.73 m2, P = 0.69).

Conclusion

This study indicated that the p.E66Q variant of GLA does not affect the progression of CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.

    Article  CAS  PubMed  Google Scholar 

  2. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.

    Article  PubMed  Google Scholar 

  4. Maruyama H, Takata T, Tsubata Y, Tazawa R, Goto K, Tohyama J, Narita I, Yoshioka H, Ishii S. Screening of male dialysis patients for Fabry disease by plasma globotriaosylsphingosine. Clin J Am Soc Nephrol. 2013;8:629–36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Kikumoto Y, Sugiyama H, Morinaga H, Inoue T, Takiue K, Kitagawa M, Saito D, Takatori Y, Kinomura M, Kitamura S, Akagi S, Sada K, Nakao K, Maeshima Y, Kitayama H, Makino H. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review. Clin Nephrol. 2012;78:224–9.

    Article  CAS  PubMed  Google Scholar 

  6. Fujii H, Kono K, Goto S, Onishi T, Kawai H, Hirata K, Hattori K, Nakamura K, Endo F, Fukagawa M. Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol. 2009;30:527–35.

    Article  PubMed  Google Scholar 

  7. Nishino T, Obata Y, Furusu A, Hirose M, Shinzato K, Hattori K, Nakamura K, Matsumoto T, Endo F, Kohno S. Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail. 2012;34:566–70.

    Article  CAS  PubMed  Google Scholar 

  8. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, Choe KH, Kim WH, Yang SH, Yoo HW. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512–7.

    Article  CAS  PubMed  Google Scholar 

  9. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S, Ohno K, Fukushige T, Kanekura T, Satomura A, Kang DH, Lee BH, Yoo HW, Doi K, Noiri E, Sakuraba H. Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. Mol Genet Metab. 2012;105:615–20.

    Google Scholar 

  10. Kobayashi M, Ohashi T, Fukuda T, Yanagisawa T, Inomata T, Nagaoka T, Kitagawa T, Eto Y, Ida H, Kusano E. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene. Mol Genet Metab. 2012;107:711–5.

    Article  CAS  PubMed  Google Scholar 

  11. Nakamura K, Sekijima Y, Nakamura K, Hattori K, Nagamatsu K, Shimizu Y, Yazaki M, Sakurai A, Endo F, Fukushima Y, Ikeda SI. p.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males. Eur J Neurol. 2014;21:49–56

    Article  CAS  PubMed  Google Scholar 

  12. Okumiya T, Ishii S, Takenaka T, Kase R, Kamei S, Sakuraba H, Suzuki Y. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun. 1995;214:1219–24.

    Article  CAS  PubMed  Google Scholar 

  13. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K. Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005;64:281–7.

    Article  CAS  PubMed  Google Scholar 

  14. Ishii S, Sakuraba H, Suzuki Y. Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet. 1992;89:29–32.

    Article  CAS  PubMed  Google Scholar 

  15. Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005;9:228–32.

    Article  CAS  PubMed  Google Scholar 

  16. Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H, Nakumura T, Kawabe M, Iino Y, Katayama Y. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol. 2000;4:49–51.

    Article  Google Scholar 

  17. Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58:548–52.

    Article  CAS  PubMed  Google Scholar 

  18. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Raychaudhuri S. Mapping rare and common causal alleles for complex human diseases. Cell. 2011;147:57–69.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Ms. Hiroko Aita for technical assistance. We are indebted to the patients, nurses, medical staff, and physicians who supported this study. This work was supported by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Science and Culture of Japan (23390223) (H.M.), and by a Grant-in-Aid for Project in Sado for Total Health (PROST) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ichiei Narita.

About this article

Cite this article

Watanabe, H., Goto, S., Miyashita, A. et al. Role of the p.E66Q variant of GLA in the progression of chronic kidney disease. Clin Exp Nephrol 19, 225–230 (2015). https://doi.org/10.1007/s10157-014-0969-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-014-0969-y

Keywords

Navigation